Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer

甲状腺癌 PI3K/Akt 通路中的分子事件

基本信息

  • 批准号:
    7728577
  • 负责人:
  • 金额:
    $ 33.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Thyroid cancer is the most common endocrine malignancy, with a rapidly rising incidence in recent years. Development of more effective management strategies for this cancer is needed and requires better understanding of its molecular mechanisms. The PI3K/Akt pathway has recently emerged as a major source of molecular derangements in thyroid cancer. In particular, genetic and epigenetic alterations within or linked to this pathway and their relationships, which have been largely unexplored, are conceivably critical molecular events in the pathogenesis of thyroid cancer. Consequently, we propose to pursue four Specific Aims to test our central hypothesis that coupling of altered methylation of important genes (e.g., tumor suppressor genes, thyroid iodide-handling genes, and oncogenes) to the PI3K/Akt pathway driven by its genetic alterations is a fundamental mechanism in thyroid cancer pathogenesis. In Specific Aim 1, we will extend our recent findings of several key genetic alterations that are most effective in activating the PI3K/Akt pathway in anaplastic thyroid cancer to explore them in a large set of follicular and papillary thyroid cancers to establish the genetic basis for a general role of the PI3K/Akt pathway in thyroid cancer. Analogous to our previous findings of aberrant gene methylation linked to the MAP kinase pathway and with our recent findings on the link of methylation of some genes to the PI3K/Akt pathway in thyroid cancer, we will investigate, in Specific Aim 2, the relationship of major genetic alterations in the PI3K/Akt pathway with methylation of known tumor suppressor and thyroid iodide-handling genes as well as potentially novel hypermethylated tumor suppressor genes and hypomethylated oncogenes coupled to the PI3K/Akt pathway that are revealed by CpG methylation microarray analysis. We further hypothesize that if the genetic and epigenetic alterations in, or linked to, the PI3K/Akt pathway are important in thyroid cancer pathogenesis, they are likely to be associated with poorer clinicopathological outcomes of thyroid cancer. This will be tested in Specific Aim 3 by examining the correlation of these genetic and epigenetic alterations with clinicopathological outcomes of thyroid cancer, a strategy that can reveal diagnostic and prognostic molecular markers. We finally hypothesize that altered methylation and, hence, expression of genes, as a consequence of aberrant PI3K/Akt pathway signaling, may be reversible by suppressing this pathway, a strategy that may have important therapeutic potential. This is to be tested in Specific Aim 4 by functionally manipulating the PI3K/Akt signaling and subsequently examining the change in methylation and expression of selected functionally important genes in thyroid cancer cell lines. This is a novel proposal that for the first time investigates both genetic and epigenetic molecular events in the PI3K/Akt pathway and their relationship as a fundamental molecular mechanism in thyroid cancer pathogenesis. With the proposed strategy to focus on selected genetic and epigenetic alterations and with the experienced laboratory of the PI that is equipped with state-of-the-art expertise and equipments for this project, successful completion of the proposed studies is expected, which should produce key insights into the molecular mechanisms of thyroid cancer pathogenesis and uncover novel diagnostic and prognostic molecular markers and therapeutic targets to improve the current management of patients with thyroid cancer. PUBLIC HEALTH RELEVANCE: Thyroid cancer is the most common malignancy of the endocrine system, with a rapidly rising incidence in the United States. Several major clinical obstacles are encountered in the management of thyroid cancer, demanding more effective strategies to overcome that can be best based on the understanding of the molecular mechanisms in the pathogenesis of this cancer. This novel project is proposed to explore particularly genetic and epigenetic alterations in the PI3K/Akt pathway and is expected to produce important insights into the molecular mechanisms of thyroid cancer pathogenesis and uncover novel molecular markers and therapeutic targets to improve the management of patients with thyroid cancer.
描述(由申请人提供):甲状腺癌是最常见的内分泌恶性肿瘤,近年来发病率迅速上升。需要为该癌症制定更有效的管理策略,并且需要更好地了解其分子机制。 PI3K/AKT途径最近已成为甲状腺癌分子扰动的主要来源。特别是,在甲状腺癌的发病机理中,人们可以想象,在很大程度上尚未探索的途径及其关系内或与其关系相关的遗传和表观遗传改变。因此,我们建议追求四个特定的目标,以测试我们的中心假设,即重要基因的甲基化偶联(例如肿瘤抑制基因,甲状腺碘化物处理基因和癌基因)与PI3K/AKT途径驱动。甲状腺癌发病机理的基本机制。在特定目标1中,我们将扩展我们最近对几种关键遗传改变的发现,这些变化最有效地激活了甲状腺质甲状腺癌中的PI3K/AKT途径,以在大量的卵泡和乳头状甲状腺癌中探索它们,以建立遗传基础,以建立遗传基础PI3K/AKT途径在甲状腺癌中的一般作用。类似于我们以前关于与MAP激酶途径相关的异常基因甲基化的发现,以及我们最近关于甲状腺癌中某些基因与PI3K/AKT途径联系的最新发现,我们将在特定的目标2中研究PI3K/AKT途径的主要遗传改变,甲基化已知的肿瘤抑制剂和甲状腺碘化物处理基因以及潜在的新型高甲基化肿瘤抑制基因以及次甲基化的肿瘤基因并偶联,并通过CPG甲基化分析揭示了PI3K/AKT途径。我们进一步假设,如果遗传和表观遗传学改变或与与甲状腺癌发病机理相关的PI3K/AKT途径很重要,则它们可能与甲状腺癌的临床病理学较差有关。这将在特定的目标3中进行测试,通过检查这些遗传和表观遗传学改变与甲状腺癌的临床病理结局的相关性,该策略可以揭示诊断和预后的分子标记。我们最终假设甲基化改变,因此,由于异常PI3K/AKT途径信号传导的结果,基因的表达可能是可以通过抑制这种途径来逆转的,该途径可能具有重要的治疗潜力。这将在特定的目标4中通过功能处理PI3K/AKT信号传导,然后检查甲状腺癌细胞系中所选功能重要基因的甲基化和表达的变化。这是一个新的建议,该建议首次研究PI3K/AKT途径中的遗传和表观遗传分子事件及其作为甲状腺癌发病机理中基本分子机制的关系。提出的策略是专注于选定的遗传和表观遗传学改变,以及经验丰富的PI实验室,该实验室配备了该项目的最先进的专业知识和设备,可以成功完成拟议的研究,这应该产生对甲状腺癌发病机理的分子机制以及发现新颖的诊断和预后的分子标记和治疗靶标,以改善甲状腺癌患者的当前治疗。公共卫生相关性:甲状腺癌是内分泌系统中最常见的恶性肿瘤,在美国发病率迅速上升。在甲状腺癌的管理中遇到了几个主要的临床障碍,要求更有效的策略克服,可以最好地基于对这种癌症发病机理的分子机制的理解。提出了这个新型项目旨在探索PI3K/AKT途径中特别遗传和表观遗传学改变,并有望对甲状腺癌发病机理的分子机制产生重要的见解,并发现新颖的分子标记和治疗靶标,以改善甲状腺癌患者管理甲状腺癌患者的管理。 。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL Mingzhao XING其他文献

MICHAEL Mingzhao XING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL Mingzhao XING', 18)}}的其他基金

TERT Promoter Mutations in Thyroid Cancer
甲状腺癌中的 TERT 启动子突变
  • 批准号:
    9029307
  • 财政年份:
    2015
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genome-wide Exploration of DNA Methylation Markers for Thyroid Cancer
甲状腺癌 DNA 甲基化标记的全基因组探索
  • 批准号:
    8634084
  • 财政年份:
    2013
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genome-wide Exploration of DNA Methylation Markers for Thyroid Cancer
甲状腺癌 DNA 甲基化标记的全基因组探索
  • 批准号:
    8492305
  • 财政年份:
    2013
  • 资助金额:
    $ 33.23万
  • 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
  • 批准号:
    8074952
  • 财政年份:
    2009
  • 资助金额:
    $ 33.23万
  • 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
  • 批准号:
    8474705
  • 财政年份:
    2009
  • 资助金额:
    $ 33.23万
  • 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
  • 批准号:
    8264949
  • 财政年份:
    2009
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genetic & Epigenetic Events in Papillary Thyroid Cancer
遗传
  • 批准号:
    7840386
  • 财政年份:
    2006
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genetic and Epigenetic Alterations in Thyroid Tumors
甲状腺肿瘤的遗传和表观遗传改变
  • 批准号:
    7432579
  • 财政年份:
    2006
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genetic and Epigenetic Alterations in Thyroid Tumors
甲状腺肿瘤的遗传和表观遗传改变
  • 批准号:
    7244434
  • 财政年份:
    2006
  • 资助金额:
    $ 33.23万
  • 项目类别:
Genetic & Epigenetic Events in Papillary Thyroid Cancer
遗传
  • 批准号:
    8577313
  • 财政年份:
    2006
  • 资助金额:
    $ 33.23万
  • 项目类别:

相似国自然基金

青藏高原“中更新世”岩面艺术的热释光年代学研究
  • 批准号:
    42371161
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
面向语义内容理解和艺术特征表示的视觉属性迁移方法研究
  • 批准号:
    62202360
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
关系地理视角下“艺术下乡”对乡村重构的过程及作用机理研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
科学与艺术的邂逅:艺术对科技创新的启示
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    10 万元
  • 项目类别:
艺术品高光谱成像数字典藏与光谱颜色再现研究
  • 批准号:
    62275025
  • 批准年份:
    2022
  • 资助金额:
    59 万元
  • 项目类别:
    面上项目

相似海外基金

(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
(PQD5) 大规模分析黑色素瘤反应以改善治疗选择和预后
  • 批准号:
    8687449
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy
黑色素瘤 T 细胞治疗中的生物标志物和耐药机制
  • 批准号:
    8673758
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy
黑色素瘤 T 细胞治疗中的生物标志物和耐药机制
  • 批准号:
    8935764
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
(PQD5) 大规模分析黑色素瘤反应以改善治疗选择和预后
  • 批准号:
    9067822
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy
黑色素瘤 T 细胞治疗中的生物标志物和耐药机制
  • 批准号:
    9143058
  • 财政年份:
    2014
  • 资助金额:
    $ 33.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了